Every morning it opens, then drops, before working its way up to the open price or thereabouts. Who I wonder is selling at start of day? |
Apologies if posted before: |
An AZ connection would be fantastic H.
CF gene therapy 4D-710 improves lung function, data show |
Yes, scale up is going from doing a process in test tubes and peach-tree dishes to making it work in a 10,000 litre bioreactor. Interestingly for the chemists and biotechs, it tends to be very non-linear, so that what you have to do to make it work, and what you get, in 10 litres is often not a simple predictor of what you get in 50 litres etc etc. That's living organisms for you. |
I think it means scaling up as part of process development - from the concept to proof of concept to actually actually being able to make a product in enough quantity for lab experiments then clinical trials, then production - i.e. the continual next step in any process upon success at the previous level (trickier than it sounds). |
'process scale up'. Scaling up suggests expansion, always a + |
 Technical Writer, Process Development
Date: 7 Jun 2024
Location: Oxford, GB
Company: oxfordbiom
We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you.
We are currently recruiting for a Technical Writer join the Process Development team (PD). The purpose of this role is to collaborate with Scientists in the effective reporting of experimental data from work carried out within the PD department, to support the delivery of feasibility studies, process development, process scale up, technical transfer and process characterisation activities.
Oxford Biomedica’s Process Development team consists of experienced Scientists, Scientific Assistants, Engineers & Writers that have extensive expertise in all aspects of upstream and downstream development. PD take processes from the laboratory “bench” scale and apply process expertise and engineering fundamentals for delivery to Manufacturing.
Your responsibilities in this role would be:
The authoring of clear and concise documentation including protocols and scientific reports to support Upstream and Downstream process development activities.
Review documentation including protocols and technical reports prior to issue to clients.
Produce and maintain technical report templates and outlines
Maintain technical report writing procedures and guidelines.
Function as department subject matter expert within Technical Writing, including training the team
Maintain a high standard of record keeping and documentation so that information is clearly captured, disseminated, and reported.
Disseminate critical findings which may have a business impact to other departments within the company.
Maintain a high ethical standard and a commitment to producing high quality work.
Ensure all scientific or proprietary data is submitted or recorded in appropriate official documentation. |
I suppose the literal million dollar question here Marcus, would be to ask if AZ (or one of the CAR-T biotech companies it has swallowed) is a confidential / undisclosed OXB vector client.
It would be very nice if that was the case.
Remember at the results they said 51 programmes with 35 clients (which will be more by now, but the results was the last figure we knew).
So out of those 35 we have 15 or 16 where we can be reasonably sure of a name:-
Arcellx
Beam Therapeutics
BMS (Juno)
Boehringer Ingelheim
Cabaletta Bio
CARGO Therapeutics
Coave Therapeutics (Old ABL)
GC Cell (Green Cross Singapore)
Geovax (Old ABL)
Immatics
Immune Design (bought by Merck)
Kyverna
Novartis
Orchard Therapeutics
RD-Biotech (Old ABL)
Sardocor
Which of course leaves 19 or 20 (at the end of April) where we could only guess. |
Armouring Car Ts may be the answer.
“armouring” element on C-CAR031 comprises a co-expressed dominant-negative TGFβ receptor that’s been truncated, so it lacks an intracellular domain necessary for downstream signalling. This feature is designed to protect the Car-T cells from TGFβ-driven immunosuppression. |
A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.
“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview. |
They are publishing early data PB.
See post 7906
Certainly won't do us any harm. |
We are in a very tight holding pattern so sifting the tea leaves to find any hopes of an exit are for passing the time of day - not taking it all too seriously alongside the technical charting stuff.... |
How big was the 'chunky buy'? Is it feasible that the 20-50k lots dumped were small enough to make the buy decently profitable? |
Well for weeks it seems some punter has been dumping 20-50k lots into the closing auction at the end of the day relentlessly.
Well today a change of something as the closing chunkier trade appears to be a buy - make of that what you will... |
We might get a shout-out.HTTps://www.linkedin.com/posts/cabalettabio_cabaletta-symposium-at-eular-2024-activity-7204895225889046529-SaDH?utm_source=share&utm_medium=member_android |
This is what accumulation looks like, designed to shake you out of your position.This chart structure was inevitable (see my earlier post), there may be a stop triggering drop before the next leg up to low 400s all imo dyor ofc. |
few buyers and sellers early on - as more arrive to trade spreads can narrow typically |
It seems now that most days at the beginning of trading there is a very large spread, up to 20p. During the day this then narrows and it ends up at the close of only about 1p. Does anyone know why ? |
I suppose what I am really saying is that it will be iteresting to watch today what technical traders do who religously follow this stuff - I am typically a LTBH so only spectate on this for background interest... |
Does anyone follow technical charting here - well if not, please ignore. But if this is of interest we have the somewhat unusual 3 white soldier bullish pattern
hxxps://cdn.howtotradeblog.com/wp-content/uploads/2020/05/30232235/where-the-pattern-appears-2-1068x670.jpg
hxxps://www.investopedia.com/terms/t/three_white_soldiers.asp
Because three white soldiers is a bullish visual pattern, it is used as a potential entry or exit point for a trade. Traders who are short on the security look to exit and traders who are waiting to take a bullish position see the three white soldiers as an entry opportunity. When trading the three white soldiers pattern, it's important to note that the strong moves higher could create temporary overbought conditions. The relative strength index (RSI), for example, may have moved above 70.0 levels. In some cases, there is a short period of consolidation following the three white soldiers pattern, but the short- and intermediate-term bias remains bullish. The significant move higher could also reach key resistance levels where the stock could experience a period of consolidation before continuing to move higher.
Limitations of Using Three White Soldiers
Three white soldiers can also appear during periods of consolidation, which is an easy way to get trapped in a continuation of the existing trend rather than a reversal. One of the key things to watch is the volume supporting the formation of three white soldiers. Any pattern on low volume is suspect because it is the market action of the few rather than the many.
dyor/nai etc |
I thought you might Dominic... |
I second that Mr President Sir. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
